
WilmerHale Reps Editas Medicine in \$94.4 Million IPO

FEBRUARY 3, 2016

WilmerHale represented Massachusetts-based gene editing company Editas Medicine in its \$94.4 million initial public offering, which occurred on February 2, 2016. The IPO was the first in the US in 2016.

The WilmerHale team on the transaction was led by Partners [Steven D. Singer](#) and [Rosemary G. Reilly](#) and included Counsel [Jeffries Oliver-Li](#), and Associates Britt Eichner and [Brett Bromann](#) (corporate); as well as Partner [Kim Wethly](#) and Counsel [Ciara Baker](#) (tax).